Skye Bioscience (SKYE) Receivables - Other (2021 - 2023)

Skye Bioscience (SKYE) posted quarterly Receivables - Other of $50000.0 for Q2 2023, up 590.99% quarter-over-quarter from $7236.0 in Q1 2023.

Skye Bioscience (SKYE) Receivables - Other (2021 - 2023) Analysis & Trends

Skye Bioscience (SKYE) has reported Receivables - Other for 3 consecutive years, with $50000.0 the latest figure, recorded in Q2 2023.

In Q2 2023, Receivables - Other changed N/A year-over-year to $50000.0; the TTM figure through Jun 2023 stood at $50000.0 (changed N/A YoY), while the FY2022 annual figure was $50000.0, up 272.25% from the prior year.
Receivables - Other climbed to $50000.0 in Q2 2023 per SKYE's latest filing, from $7236.0 in the prior quarter.
Across five years, Receivables - Other topped out at $50000.0 in Q3 2022 and bottomed at $7236.0 in Q1 2023.
Historically, Receivables - Other has averaged $31563.2 across 3 years, with a median of $33516.5 in 2021.
Annual changes were most pronounced in 2022 — Receivables - Other soared 272.25% — and 2023, when it sank 85.2%.
Skye Bioscience's Receivables - Other stood at $13432.0 in 2021, then jumped by 272.25% to $50000.0 in 2022, then changed by 0.0% to $50000.0 in 2023.
Business Quant data shows SKYE's Receivables - Other at $50000.0 in Q2 2023, $7236.0 in Q1 2023, and $50000.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.84 Bn	131.99 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.48 Bn	78.49 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	60.15 Bn	55.01 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	28.54 Bn	10.14 Bn	668.28 Mn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn
9	Royalty Pharma	27.22 Bn	26.38 Bn	-
10	Skye Bioscience	10.72 Mn	10.72 Mn	-

Download Data